Sonoma BioTherapeutics: Funding, Investors & Team (Sep 2026)
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Sonoma BioTherapeutics has raised $295M across 3 funding rounds on record, the most recent an undisclosed round of $300k announced in Nov 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Sonoma BioTherapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Sonoma BioTherapeutics Funding Rounds
Sonoma BioTherapeutics raised $265M in a Series B announced in Aug 2021.
1.6 years later, an undisclosed round of $30.0M was announced in Mar 2023.
2.7 years later, an undisclosed round of $300k was announced in Nov 2025.
Sonoma BioTherapeutics Founders and Leadership Team
Contact details for the Sonoma BioTherapeutics team: 2 of 2 have an email address on file.
Start 14-day free trial →Sonoma BioTherapeutics Funding Compared to Other Biotechnology Startups
Sonoma BioTherapeutics' latest round of $300k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Sonoma BioTherapeutics in Biotechnology and South San Francisco
Companies Similar to Sonoma BioTherapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Sonoma BioTherapeutics Funding FAQs
What does Sonoma BioTherapeutics do?
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
How much funding has Sonoma BioTherapeutics raised?
Sonoma BioTherapeutics has raised $295M across 3 rounds on record. The most recent is an undisclosed round of $300k announced in Nov 2025.
When did Sonoma BioTherapeutics last raise funding?
Sonoma BioTherapeutics' most recent funding round on record is an undisclosed round of $300k, announced in Nov 2025.
Who founded Sonoma BioTherapeutics?
FundedIQ lists Qizhi Tang (Founder) at Sonoma BioTherapeutics.
Who is the CEO of Sonoma BioTherapeutics?
Jeffrey Bluestone is listed as CEO at Sonoma BioTherapeutics.
Where is Sonoma BioTherapeutics headquartered?
Sonoma BioTherapeutics is based in South San Francisco, California, United States.
How many employees does Sonoma BioTherapeutics have?
Sonoma BioTherapeutics is in the 11-50 employee band.
How does Sonoma BioTherapeutics' funding compare to other Biotechnology startups?
Sonoma BioTherapeutics' latest round of $300k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Sonoma BioTherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Sonoma BioTherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.